1. Home
  2. ELDN vs PALI Comparison

ELDN vs PALI Comparison

Compare ELDN & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$1.97

Market Cap

219.4M

Sector

Health Care

ML Signal

HOLD

Logo Palisade Bio Inc.

PALI

Palisade Bio Inc.

SELL

Current Price

$1.00

Market Cap

249.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ELDN
PALI
Founded
2004
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.4M
249.2M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
ELDN
PALI
Price
$1.97
$1.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
10
Target Price
★ $9.00
$8.70
AVG Volume (30 Days)
918.4K
★ 2.8M
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
30.67
★ 97.06
EPS
N/A
★ N/A
Revenue
N/A
★ $260,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1500.39
52 Week Low
$1.35
$1.01
52 Week High
$4.49
$2.86

Technical Indicators

Market Signals
Indicator
ELDN
PALI
Relative Strength Index (RSI) 35.64 31.01
Support Level N/A N/A
Resistance Level $3.14 $2.18
Average True Range (ATR) 0.27 0.09
MACD -0.07 -0.00
Stochastic Oscillator 3.83 3.23

Price Performance

Historical Comparison
ELDN
PALI

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About PALI Palisade Bio Inc.

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Share on Social Networks: